Therapy Detail

Therapy Name PBF-509
Synonym
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
PBF-509 NIR178 Immune Checkpoint Inhibitor 99 PBF-509 binds to and inhibits the adenosine A2A (ADORA2A) receptor on immune cells, resulting in activation of an anti-tumor immune response by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29758241, PMID: 28582704).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02403193 Phase Ib/II PBF-509 + Spartalizumab PBF-509 Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO) Recruiting